Denovo takes on failed Lilly cancer drug
This article was originally published in Scrip
San Diego firm Denovo Biopharma is hoping to breathe fresh life into a drug written off by Lilly after it failed late-stage trials. The privately held biotech company believes that its technology for discovering biomarkers using archived clinical trial samples may enable it to identify subsets of patients who are more likely to respond to treatment with the drug, enzastaurin. It has acquired all rights to the drug worldwide.
You may also be interested in...
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are 12 new oncology products developed to treat hematological malignancies that, if successful at the regulators, are due to be launched for the first time next year.
From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.
A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.